Topical Use of Recombinant Human Epidermal Growth Factor (EGF)-Based Cream to Prevent Radiation Dermatitis in Breast Cancer Patients: a Single-Blind Randomized Preliminary Study

• DOI: 10.7314/apjcp.2013.14.8.4859
• Publication Date: 2013-11-26T05:55:32Z
• Authors: Moonkyoo Kong; Seong Eon Hong
• Keywords: Adult; Epidermal Growth Factor; Radiotherapy; Administration, Topical; Incidence; Breast Neoplasms; Middle Aged; Prognosis; Recombinant Proteins; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Case-Control Studies; Republic of Korea; Humans; Female; Single-Blind Method; Prospective Studies; Radiodermatitis; Aged; Follow-Up Studies; Neoplasm Staging

Background: The purpose of this study was to assess the effectiveness a recombinant human epidermal growth factor (EGF)-based cream for prevention acute radiation dermatitis in breast cancer patients receiving radiotherapy (RT). Materials and Methods: Between December 2012 April 2013, 40 who received postoperative RT were prospectively enrolled randomly assigned receive EGF-based (intervention group) or general supportive skin care (control group). grade pain score examined at weekly intervals during 6 weeks after completion. Results: All completed planned complied well with instructions applying care. In intervention group, maximum 3, 2, 1 developed 3 (15%), 11 (55%), (30%), respectively. comparison, control 8 (40%), 10 (50%), 2 (10%), group showed lower incidence than (p=0.068 univariate analysis p=0.035 multivariate analysis). There no statistically significant difference maximal between two groups (p=0.934). Conclusions: This single-blind randomized preliminary that can have beneficial role preventing minimizing patients. To confirm results our study, additional studies large sample size are required.